文献速递神经肿瘤

胶质瘤生物标志物指导的治疗策略:临床应用进展

Biomarker-guided treatment strategies for patients with gliomas in clinical practice.
PubMed 文献 · Neuro Oncol · 2026-10-19

该综述指出靶向治疗在胶质母细胞瘤中因通路冗余和缺乏合适靶点而疗效有限,但在非胶质母细胞瘤中已有改变临床实践的进展:vorasidenib成为首个获批用于IDH突变胶质瘤的药物,dordaviprone在复发K27M突变弥漫性中线胶质瘤中显示潜在活性。改进临床试验设计(共享对照臂、药效学终点、富集人群)是未来方向。

要点

  • vorasidenib是首个获批专门用于IDH突变胶质瘤的靶向药物,改变了WHO 2级胶质瘤治疗格局。
  • dordaviprone在复发K27M突变弥漫性中线胶质瘤患者中显示潜在活性。
  • 胶质母细胞瘤靶向治疗失败主因是致癌通路冗余和缺乏生物标志物富集策略。

核心结论

  • 靶向治疗在胶质母细胞瘤中活性有限,但在IDH突变胶质瘤和K27M突变弥漫性中线胶质瘤等非胶质母细胞瘤中已取得改变临床实践的进展。

研究设计与样本

  • 综述类文章,检索范围未在摘要中明确报告。

主要发现

  • vorasidenib作为首个获批专门用于IDH突变胶质瘤的药物,改变了WHO 2级胶质瘤的靶向治疗格局。
  • dordaviprone作为DRD2/3拮抗剂和ClpP变构激动剂,在复发K27M突变弥漫性中线胶质瘤患者中显示潜在活性。
  • BRAF突变、NTRK基因融合和FGFR基因融合至少对部分胶质瘤患者继续作为有吸引力的治疗靶点。
  • 室管膜瘤几乎尚无靶向治疗策略出现。

关键数值与推荐

  • vorasidenib是首个获批专门用于IDH突变胶质瘤的靶向药物。
  • dordaviprone是DRD2/3拮抗剂和ClpP变构激动剂。

临床怎么用

  • 对IDH突变WHO 2级胶质瘤可考虑vorasidenib靶向治疗。
  • 对复发K27M突变弥漫性中线胶质瘤可关注dordaviprone的潜在治疗活性。
  • 对部分胶质瘤患者可评估BRAF突变、NTRK融合和FGFR融合作为治疗靶点。

局限性

  • 靶向治疗在胶质母细胞瘤中因致癌通路冗余和缺乏合适靶点而活性有限。
  • 室管膜瘤几乎尚无靶向治疗策略出现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeted therapy has made important contributions to improving outcomes for patients with many solid tumors, but has had only limited activity so far in patients with gliomas, notably glioblastoma. Failure of targeted therapy in glioblastoma is likely due to redundance of oncogenic pathway activation and so far the inability to identify suitable targets and apply biomarker-based enrichment strategies in clinical trial designs. In contrast, in non-glioblastoma tumors, there are promising developments which have already changed clinical practice: inhibition of mutant isocitrate dehydrogenase (IDH) exemplified by vorasidenib, the first approved drug specifically for IDH-mutant gliomas, has changed the landscape for targeted therapy of WHO grade 2 gliomas. Furthermore, dordaviprone, an antagonist of dopamine receptor D2/3 (DRD2/3) and an allosteric agonist of the mitochondrial protease caseinolytic mitochondrial matrix peptidase proteolytic subunit (ClpP), emerges as a potentially active agent in patients with recurrent K27M-mutant diffuse midline gliomas. Finally, BRAF mutations, neurotrophic tyrosine receptor kinase ( r fibroblast growth factor receptor (FGFR) gene fusions continue to raise interest as therapeutic targets at least for subsets of patients with gliomas. Almost no targeted therapy approaches for ependymomas have emerged. Improved clinical trial designs including shared control arms early on and using pharmacodynamic endpoints ideally in enriched patient populations are the path forward towards the identification of further active treatments for patients with gliomas. Targeted therapy defines treatment strategies that are designed to interfere with a specific metabolic signaling pathway that maintains growth of a specific type of tumor. Among primary brain tumors, dependence of growth on one single signaling pathway is rare. This has limited the role of targeted therapy, notably in glioblastoma, the most common primary malignant brain tumor in adults. In some brain tumors other than glioblastoma, there are promising developments which have already changed clinical practice, notably inhibition of mutant isocitrate dehydrogenase (IDH) in tumors with IDH mutations. Novel targets are currently being explored in various types of rare brain tumors.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Le Rhun E, Mellinghoff IK, Weiss T, et al. Biomarker-guided treatment strategies for patients with gliomas in clinical practice. Neuro Oncol. 2026. PMID: 42895284. doi:10.1093/neuonc/noag238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。